The Filing Desk

Inogen vs PROCEPT BioRobotics

Inogen INGN · PROCEPT BioRobotics PRCT · Health Care Equipment

Inogen reported revenue of $349 million in fiscal 2025, about the same as PROCEPT BioRobotics' $308 million in fiscal 2025. Inogen's revenue grew 3.9% in its latest year, and PROCEPT BioRobotics' grew 37.2%. Inogen had an operating margin of -8.7%, against -33.7% at PROCEPT BioRobotics. Free cash flow was −$14 million at Inogen and −$58 million at PROCEPT BioRobotics.

Side by side

InogenPROCEPT BioRobotics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$349M$308M
Revenue growth3.9%37.2%
Revenue growth a year, last 5 years2.5%109.1%
Gross margin44.2%63.7%
Operating margin−8.7%−33.7%
Net margin−6.5%−31.0%
Free cash flow−$14M−$58M
Free cash flow margin−3.9%−18.9%
Return on capital—−65.4%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count12.5%6.6%
Last close$5.42$25.75
P/E at the last close——
Insider trades, last 12 monthssold $142,519bought $11.0 million, sold $616,004
Piotroski F-score—5 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
InogenPROCEPT BioRobotics
Operating margin
Percent of revenue
InogenPROCEPT BioRobotics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InogenPROCEPT BioRobotics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Inogen and PROCEPT BioRobotics pages.